众兴菌业(002772) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥586,109,725.32, representing a 65.22% increase compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2022 was ¥138,407,977.41, a significant increase of 324.92% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥126,070,410.23, reflecting a 481.99% increase compared to the previous year[4] - Total operating revenue for Q3 2022 reached CNY 1,444,886,177.51, a 36.4% increase from CNY 1,059,099,172.23 in the same period last year[23] - Net profit for Q3 2022 was CNY 118,632,727.72, compared to a net loss of CNY 49,673,704.39 in Q3 2021, marking a significant turnaround[24] - Operating profit for the quarter was CNY 124,607,575.63, a recovery from an operating loss of CNY 32,511,354.52 in the previous year[23] - Basic and diluted earnings per share for Q3 2022 were CNY 0.3055, recovering from a loss of CNY 0.1356 per share in the same quarter last year[24] - The basic earnings per share for Q3 2022 was ¥0.3572, representing a 325.51% increase compared to the same period last year[4] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥6,769,148,386.26, which is a 3.33% increase from the end of the previous year[4] - The company's total assets as of September 30, 2022, amount to ¥6,769,148,386.26, an increase from ¥6,551,297,202.04 at the beginning of the year[20][21] - Current assets total ¥3,318,633,200.95, compared to ¥3,078,539,537.78 at the beginning of the year, reflecting a growth of approximately 7.8%[20] - Total liabilities increased to ¥3,426,177,374.22 from ¥3,300,170,250.21, indicating a growth of approximately 3.8%[21] - The company's equity attributable to shareholders increased to ¥3,340,187,434.71 from ¥3,248,600,124.87, reflecting an increase of about 2.8%[21] Cash Flow - The cash flow from operating activities for the first nine months of 2022 was ¥343,699,036.51, up 127.09% year-on-year[14] - Cash flow from operating activities generated CNY 343,699,036.51, a substantial increase from CNY 151,349,616.18 in the same quarter last year[25] - The company's investment activities generated a net cash flow of -¥625,520,712.28 for the first nine months of 2022, compared to -¥244,349,843.02 in the previous year[14] - Investment activities resulted in a net cash outflow of CNY 625,520,712.28, compared to a net outflow of CNY 244,349,843.02 in the previous year[25] - Financing activities generated a net cash inflow of CNY 40,666,662.64, a decrease from CNY 580,304,161.29 in Q3 2021[26] Shareholder Information - The total number of common shareholders at the end of the reporting period is 39,181[16] - The largest shareholder, Tao Jun, holds 27.03% of shares, amounting to 110,136,094 shares, with 42,150,000 shares pledged[16] - The company holds 14,536,516 shares in its repurchase account, accounting for 3.57% of the total share capital[17] - The company has a total of 1.76% of shares held by the state-owned entity, Great Wall Guorong Investment Management Co., Ltd.[17] Research and Development - The company's R&D expenses for the first nine months of 2022 were ¥9,503,019.60, an increase of 71.45% compared to the same period last year[12] - Research and development expenses increased to CNY 9,503,019.60, up 71.5% from CNY 5,542,665.57 in the prior year[23] Other Financial Metrics - The company's cash and cash equivalents decreased to ¥1,339,635,959.91 from ¥1,595,197,988.30, a decline of about 16.1%[20] - Short-term borrowings increased to ¥215,000,000.00 from ¥150,000,000.00, representing a rise of 43.3%[21] - The company's financial expenses for the first nine months of 2022 were ¥46,839,656.77, an increase of 86.29% year-on-year[12] - Total operating costs amounted to CNY 1,310,925,671.09, up 19.1% from CNY 1,100,766,880.41 year-over-year[23] Reporting and Governance - The third quarter report of Tianshui Zhongxing Mushroom Industry Technology Co., Ltd. is unaudited[27] - The board of directors meeting was held on October 11, 2022[28]